Thus, the inhibitors of Gal-3 have demonstrated effects in reducing lung metastasis, proliferation, and tumor growth and exhibit synergic effects with chemotherapy [29,30]; clinical studies are ongoing with melanoma patients, using Gal-3 inhibitor GR-MD-02 and ipilimumab (Clinical trial NCT02117362) [31]. This evidence concerns the gene LGALS3 and melanoma.